JP2010529994A5 - - Google Patents

Download PDF

Info

Publication number
JP2010529994A5
JP2010529994A5 JP2010512352A JP2010512352A JP2010529994A5 JP 2010529994 A5 JP2010529994 A5 JP 2010529994A5 JP 2010512352 A JP2010512352 A JP 2010512352A JP 2010512352 A JP2010512352 A JP 2010512352A JP 2010529994 A5 JP2010529994 A5 JP 2010529994A5
Authority
JP
Japan
Prior art keywords
compound
deuterium
hydrogen
independently
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010512352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529994A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/066730 external-priority patent/WO2008157240A1/en
Publication of JP2010529994A publication Critical patent/JP2010529994A/ja
Publication of JP2010529994A5 publication Critical patent/JP2010529994A5/ja
Pending legal-status Critical Current

Links

JP2010512352A 2007-06-13 2008-06-12 置換ピペラジン Pending JP2010529994A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94373107P 2007-06-13 2007-06-13
PCT/US2008/066730 WO2008157240A1 (en) 2007-06-13 2008-06-12 Substituted piperazines

Publications (2)

Publication Number Publication Date
JP2010529994A JP2010529994A (ja) 2010-09-02
JP2010529994A5 true JP2010529994A5 (en:Method) 2011-07-28

Family

ID=39609397

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010512352A Pending JP2010529994A (ja) 2007-06-13 2008-06-12 置換ピペラジン

Country Status (9)

Country Link
US (2) US20080312247A1 (en:Method)
EP (1) EP2155697B1 (en:Method)
JP (1) JP2010529994A (en:Method)
KR (1) KR20100047190A (en:Method)
CN (1) CN101835761A (en:Method)
AU (1) AU2008266124A1 (en:Method)
CA (1) CA2690379A1 (en:Method)
IL (1) IL202666A0 (en:Method)
WO (1) WO2008157240A1 (en:Method)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2395241T3 (es) * 2007-03-07 2013-02-11 Concert Pharmaceuticals Inc. Derivados deuterados de piperazina como compuestos antianginosos
US20110053968A1 (en) 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
JP2013506687A (ja) 2009-09-30 2013-02-28 プレジデント アンド フェロウズ オブ ハーバード カレッジ オートファジー促進遺伝子産物の変調によりオートファジーを変調する方法
CN101811941A (zh) * 2010-03-12 2010-08-25 重庆欣欣向荣精细化工有限公司 邻羟基苯基烷基醚的制备方法
CN102295622A (zh) 2010-06-25 2011-12-28 上海冠杰生物医药科技有限公司 一种雷诺嗪的制备方法
EP2524688B1 (en) * 2011-05-11 2013-05-01 ratiopharm GmbH Composition for modified release comprising ranolazine
US10463611B2 (en) * 2011-06-08 2019-11-05 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
WO2014164767A1 (en) 2013-03-13 2014-10-09 Forma Therapeutics, Inc. Novel compounds and compositions for inhibition of fasn
EP2968327A4 (en) * 2013-03-14 2016-09-28 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
WO2015048311A1 (en) * 2013-09-25 2015-04-02 Cortendo Ab (Publ) Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibitng cytochrome p450 inhibition
US10166183B2 (en) 2014-02-07 2019-01-01 Auspex Pharmaceuticals, Inc. Pharmaceutical formulations
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
CN116251072B (zh) * 2023-03-14 2023-09-15 郑州大学第一附属医院 一种吲哚布芬片及其制备方法、用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6884429B2 (en) * 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
ATE234299T1 (de) * 1999-12-03 2003-03-15 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
US6396062B1 (en) * 1999-12-03 2002-05-28 Cymer, Inc. Portable laser beam monitor
EP1134290A3 (en) * 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
WO2006008753A1 (en) * 2004-07-19 2006-01-26 Unichem Laboratories Limited Crystalline and amorphous form of ranolazine and the process for manufacturing them
AR054583A1 (es) * 2005-07-26 2007-06-27 Altana Pharma Ag Pantoprazol isotopicamente sustituido
ES2396365T3 (es) * 2005-07-29 2013-02-21 Concert Pharmaceuticals Inc. Nuevos derivados de benzo[D][1,3]-dioxol deuterados como inhibidores de la recaptación de serotonina
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
ES2395241T3 (es) * 2007-03-07 2013-02-11 Concert Pharmaceuticals Inc. Derivados deuterados de piperazina como compuestos antianginosos

Similar Documents

Publication Publication Date Title
JP2010529994A5 (en:Method)
JP2010530897A5 (en:Method)
JP2010095546A5 (en:Method)
JP2013032389A5 (en:Method)
JP2013505929A5 (en:Method)
JP2014500861A5 (en:Method)
JP2011518833A5 (en:Method)
JP2007302689A5 (en:Method)
JP2012532883A5 (en:Method)
JP2006526031A5 (en:Method)
JP2012092103A5 (en:Method)
JP2015501820A5 (en:Method)
HRP20221304T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
EP4245369A3 (en) Neuroactive steroids, compositions, and uses thereof
JP2011121940A5 (ja) 発光素子
JP2013514980A5 (en:Method)
JP2010540477A5 (en:Method)
WO2010132765A3 (en) Antibacterial aminoglycoside analogs
JP2010520214A5 (en:Method)
MX2011013648A (es) Nuevos compuestos, composiciones farmaceuticas y metodos relacionados con ellos.
JP2012254971A5 (ja) カルバゾール化合物
JP2010534246A5 (en:Method)
ATE537136T1 (de) Neues verfahren zur herstellung von säurechloriden
JP2012518649A5 (en:Method)
JP2012511558A5 (en:Method)